Literature DB >> 17641667

Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences.

J M McPartland1, M Glass, R G Pertwee.   

Abstract

A meta-analysis, unlike a literature review, synthesizes previous studies into new results. Pooled data from 211 studies measured ligand binding affinities at human (Hs) or rat (Rn) cannabinoid receptors CB1 and CB2. Cochrane methods were modified for this non-clinical analysis. Meta-regression detected data heterogeneity arising from methodological factors: use of sectioned tissues, lack of PMSF and choice of radioligand. Native brain tissues exhibited greater affinity (lower nM) than transfected cells, but the trend fell short of significance, as did the trend between centrifugation and filtration methods. Correcting for heterogeneity, mean Ki values for delta 9-tetrahydrocannabinol differed significantly between HsCB1 and RnCB1 (25.1 and 42.6 nM, respectively) but not between HsCB1 and HsCB2 (25.1 and 35.2). Mean Kd values for HsCB1, RnCB1 and HsCB2 of CP55,940 (2.5, 0.98, 0.92) and WIN55,212-2 (16.7, 2.4, 3.7) differed between HsCB1 and RnCB1 and between HsCB1 and HsCB2. SR141716A differed between HsCB1 and RnCB1 (2.9 and 1.0 nM). Anandamide at HsCB1, RnCB1 and HsCB2 (239.2, 87.7, 439.5) fell short of statistical differences due to heterogeneity. We consider these Kd and Ki values to be the most valid estimates in the literature. Sensitivity analyses did not support the numerical validity of cannabidiol, cannabinol, 2-arachidonoyl glycerol and all ligands at RnCB2. Aggregate rank order analysis of CB(1) distribution in the brain (pooled from 119 autoradiographic, immunohistochemical and in situ hybridization studies) showed denser HsCB1 expression in cognitive regions (cerebral cortex) compared to RnCB1, which was relatively richer in movement-associated areas (cerebellum, caudate-putamen). Implications of interspecies differences are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641667      PMCID: PMC2190026          DOI: 10.1038/sj.bjp.0707399

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

1.  Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A.

Authors:  F Petitet; L Marin; A Doble
Journal:  Neuroreport       Date:  1996-02-29       Impact factor: 1.837

2.  Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain.

Authors:  M Glass; M Dragunow; R L Faull
Journal:  Neuroscience       Date:  1997-03       Impact factor: 3.590

3.  Discrepancies between meta-analyses and subsequent large randomized, controlled trials.

Authors:  J LeLorier; G Grégoire; A Benhaddad; J Lapierre; F Derderian
Journal:  N Engl J Med       Date:  1997-08-21       Impact factor: 91.245

4.  Regional differences in cannabinoid receptor/G-protein coupling in rat brain.

Authors:  C S Breivogel; L J Sim; S R Childers
Journal:  J Pharmacol Exp Ther       Date:  1997-09       Impact factor: 4.030

5.  Improved discriminatory properties between human and murine tachykinin NK1 receptors of MEN 10930: a new potent and competitive antagonist.

Authors:  M Astolfi; R Patacchini; M Maggi; S Manzini
Journal:  Neuropeptides       Date:  1997-08       Impact factor: 3.286

6.  Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase.

Authors:  M H Rhee; Z Vogel; J Barg; M Bayewitch; R Levy; L Hanus; A Breuer; R Mechoulam
Journal:  J Med Chem       Date:  1997-09-26       Impact factor: 7.446

7.  Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.

Authors:  T Sheskin; L Hanus; J Slager; Z Vogel; R Mechoulam
Journal:  J Med Chem       Date:  1997-02-28       Impact factor: 7.446

Review 8.  The vanilloid (capsaicin) receptor: receptor types and species differences.

Authors:  A Szallasi
Journal:  Gen Pharmacol       Date:  1994-03

9.  Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment.

Authors:  F Rodríguez de Fonseca; M A Gorriti; J J Fernández-Ruiz; T Palomo; J A Ramos
Journal:  Pharmacol Biochem Behav       Date:  1994-01       Impact factor: 3.533

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  79 in total

1.  The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.

Authors:  A Chicca; J Marazzi; J Gertsch
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

2.  Cannabinoids and their actions.

Authors:  S P H Alexander; M Randall
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

3.  Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands.

Authors:  Q-R Liu; C-H Pan; A Hishimoto; C-Y Li; Z-X Xi; A Llorente-Berzal; M-P Viveros; H Ishiguro; T Arinami; E S Onaivi; G R Uhl
Journal:  Genes Brain Behav       Date:  2009-06-03       Impact factor: 3.449

4.  CBD: A New Hope?

Authors:  Paula Morales; Patricia H Reggio
Journal:  ACS Med Chem Lett       Date:  2019-04-29       Impact factor: 4.345

Review 5.  Neurobiological Interactions Between Stress and the Endocannabinoid System.

Authors:  Maria Morena; Sachin Patel; Jaideep S Bains; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

6.  Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.

Authors:  David R Janero; Suma Yaddanapudi; Nikolai Zvonok; Kumar V Subramanian; Vidyanand G Shukla; Edward Stahl; Lei Zhou; Dow Hurst; James Wager-Miller; Laura M Bohn; Patricia H Reggio; Ken Mackie; Alexandros Makriyannis
Journal:  ACS Chem Neurosci       Date:  2015-05-29       Impact factor: 4.418

Review 7.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

8.  Effects of oral Δ9-tetrahydrocannabinol on the cerebral processing of olfactory input in healthy non-addicted subjects.

Authors:  Carmen Walter; Bruno G Oertel; Lisa Felden; Ulrike Nöth; Johannes Vermehren; Ralf Deichmann; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2017-09-02       Impact factor: 2.953

9.  Affinity and Efficacy Studies of Tetrahydrocannabinolic Acid A at Cannabinoid Receptor Types One and Two.

Authors:  John M McPartland; Christa MacDonald; Michelle Young; Phillip S Grant; Daniel P Furkert; Michelle Glass
Journal:  Cannabis Cannabinoid Res       Date:  2017-05-01

Review 10.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.